SUDS3 and cancer: We observed significantly enhanced target gene repression in K562 and Jurkat cells expressing dCas9-SALL1-SDS3 than in those expressing dCas9-KRAB and similarly robust levels of target repression in both A375 cell lines (75–81% with dCas9-SALL1-SDS3, 63–85% with dCas9-KRAB) (Fig. 2C), indicating the system is broadly applicable across different cancer cell lines.